HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 36
Summary
- Conditions
- Atypical Teratoid/Rhabdoid Tumor
- Central Nervous System Tumor, Pediatric
- Choroid Plexus Carcinoma
- Ependymoma
- Germ Cell Tumor
- Glioma
- Medulloblastoma
- Pineoblastoma
- Primitive Neuroectodermal Tumor
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 1 years and 26 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03500991
- Collaborators
- Not Provided
- Investigators
- Study Chair: Nicholas Vitanza, MD Seattle Children's Hospital